The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2020

Filed:

Jul. 10, 2017
Applicant:

Macau University of Science and Technology, Taipa, MO;

Inventors:

Liang Liu, Taipa, MO;

Kam Wai Wong, Taipa, MO;

Yuen Kwan Law, Taipa, MO;

Cong Ling Qiu, Taipa, MO;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/185 (2006.01); A61K 31/495 (2006.01); A61K 31/56 (2006.01); A61K 31/519 (2006.01); A61K 31/573 (2006.01); A61K 31/165 (2006.01); A61K 31/42 (2006.01); A61K 45/06 (2006.01); A61K 31/635 (2006.01); A61K 31/19 (2006.01); A61K 39/00 (2006.01); A61K 31/365 (2006.01);
U.S. Cl.
CPC ...
A61K 31/56 (2013.01); A61K 31/165 (2013.01); A61K 31/19 (2013.01); A61K 31/365 (2013.01); A61K 31/42 (2013.01); A61K 31/519 (2013.01); A61K 31/573 (2013.01); A61K 31/635 (2013.01); A61K 39/00 (2013.01); A61K 45/06 (2013.01);
Abstract

A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.


Find Patent Forward Citations

Loading…